Cargando…

Targeting Adiponectin in Breast Cancer

Obesity and breast cancer are two major health issues that could be categorized as sincere threats to human health. In the last few decades, the relationship between obesity and cancer has been well established and extensively investigated. There is strong evidence that overweight and obesity increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nehme, Rawan, Diab-Assaf, Mona, Decombat, Caroline, Delort, Laetitia, Caldefie-Chezet, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687473/
https://www.ncbi.nlm.nih.gov/pubmed/36428526
http://dx.doi.org/10.3390/biomedicines10112958
_version_ 1784836014045396992
author Nehme, Rawan
Diab-Assaf, Mona
Decombat, Caroline
Delort, Laetitia
Caldefie-Chezet, Florence
author_facet Nehme, Rawan
Diab-Assaf, Mona
Decombat, Caroline
Delort, Laetitia
Caldefie-Chezet, Florence
author_sort Nehme, Rawan
collection PubMed
description Obesity and breast cancer are two major health issues that could be categorized as sincere threats to human health. In the last few decades, the relationship between obesity and cancer has been well established and extensively investigated. There is strong evidence that overweight and obesity increase the risk of postmenopausal breast cancer, and adipokines are the central players in this relationship. Produced and secreted predominantly by white adipose tissue, adiponectin is a bioactive molecule that exhibits numerous protective effects and is considered the guardian angel of adipokine. In the obesity–cancer relationship, more and more evidence shows that adiponectin may prevent and protect individuals from developing breast cancer. Recently, several updates have been published on the implication of adiponectin in regulating tumor development, progression, and metastases. In this review, we provide an updated overview of the metabolic signaling linking adiponectin and breast cancer in all its stages. On the other hand, we critically summarize all the available promising candidates that may reactivate these pathways mainly by targeting adiponectin receptors. These molecules could be synthetic small molecules or plant-based proteins. Interestingly, the advances in genomics have made it possible to create peptide sequences that could specifically replace human adiponectin, activate its receptor, and mimic its function. Thus, the obvious anti-cancer activity of adiponectin on breast cancer should be better exploited, and adiponectin must be regarded as a serious biomarker that should be targeted in order to confront this threatening disease.
format Online
Article
Text
id pubmed-9687473
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96874732022-11-25 Targeting Adiponectin in Breast Cancer Nehme, Rawan Diab-Assaf, Mona Decombat, Caroline Delort, Laetitia Caldefie-Chezet, Florence Biomedicines Review Obesity and breast cancer are two major health issues that could be categorized as sincere threats to human health. In the last few decades, the relationship between obesity and cancer has been well established and extensively investigated. There is strong evidence that overweight and obesity increase the risk of postmenopausal breast cancer, and adipokines are the central players in this relationship. Produced and secreted predominantly by white adipose tissue, adiponectin is a bioactive molecule that exhibits numerous protective effects and is considered the guardian angel of adipokine. In the obesity–cancer relationship, more and more evidence shows that adiponectin may prevent and protect individuals from developing breast cancer. Recently, several updates have been published on the implication of adiponectin in regulating tumor development, progression, and metastases. In this review, we provide an updated overview of the metabolic signaling linking adiponectin and breast cancer in all its stages. On the other hand, we critically summarize all the available promising candidates that may reactivate these pathways mainly by targeting adiponectin receptors. These molecules could be synthetic small molecules or plant-based proteins. Interestingly, the advances in genomics have made it possible to create peptide sequences that could specifically replace human adiponectin, activate its receptor, and mimic its function. Thus, the obvious anti-cancer activity of adiponectin on breast cancer should be better exploited, and adiponectin must be regarded as a serious biomarker that should be targeted in order to confront this threatening disease. MDPI 2022-11-17 /pmc/articles/PMC9687473/ /pubmed/36428526 http://dx.doi.org/10.3390/biomedicines10112958 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nehme, Rawan
Diab-Assaf, Mona
Decombat, Caroline
Delort, Laetitia
Caldefie-Chezet, Florence
Targeting Adiponectin in Breast Cancer
title Targeting Adiponectin in Breast Cancer
title_full Targeting Adiponectin in Breast Cancer
title_fullStr Targeting Adiponectin in Breast Cancer
title_full_unstemmed Targeting Adiponectin in Breast Cancer
title_short Targeting Adiponectin in Breast Cancer
title_sort targeting adiponectin in breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687473/
https://www.ncbi.nlm.nih.gov/pubmed/36428526
http://dx.doi.org/10.3390/biomedicines10112958
work_keys_str_mv AT nehmerawan targetingadiponectininbreastcancer
AT diabassafmona targetingadiponectininbreastcancer
AT decombatcaroline targetingadiponectininbreastcancer
AT delortlaetitia targetingadiponectininbreastcancer
AT caldefiechezetflorence targetingadiponectininbreastcancer